South Korea
· Delayed Price · Currency is KRW CHA Vaccine Research Institute Statistics
Total Valuation
CHA Vaccine Research Institute has a market cap or net worth of KRW 107.73 billion. The enterprise value is 77.39 billion.
| Market Cap | 107.73B |
| Enterprise Value | 77.39B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
CHA Vaccine Research Institute has 26.73 million shares outstanding. The number of shares has increased by 1.60% in one year.
| Shares Outstanding | 26.73M |
| Shares Change (YoY) | +1.60% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 1.56% |
| Owned by Institutions (%) | 0.02% |
| Float | 15.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 291.79 |
| PB Ratio | 3.43 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.36 |
| EV / Sales | 208.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.03 |
Financial Position
The company has a current ratio of 57.40, with a Debt / Equity ratio of 0.15.
| Current Ratio | 57.40 |
| Quick Ratio | 53.01 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.81 |
| Interest Coverage | -4.14 |
Financial Efficiency
Return on equity (ROE) is -13.93% and return on invested capital (ROIC) is -9.65%.
| Return on Equity (ROE) | -13.93% |
| Return on Assets (ROA) | -8.89% |
| Return on Capital (ROIC) | -9.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.79% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -21.79% |
| 50-Day Moving Average | 4,357.30 |
| 200-Day Moving Average | 4,820.23 |
| Relative Strength Index (RSI) | 38.89 |
| Average Volume (20 Days) | 41,699 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CHA Vaccine Research Institute had revenue of KRW 370.66 million and -4.46 billion in losses. Loss per share was -166.09.
| Revenue | 370.66M |
| Gross Profit | 346.73M |
| Operating Income | -7.22B |
| Pretax Income | -4.81B |
| Net Income | -4.46B |
| EBITDA | -6.68B |
| EBIT | -7.22B |
| Loss Per Share | -166.09 |
Balance Sheet
The company has 35.15 billion in cash and 4.81 billion in debt, giving a net cash position of 30.34 billion or 1,135.10 per share.
| Cash & Cash Equivalents | 35.15B |
| Total Debt | 4.81B |
| Net Cash | 30.34B |
| Net Cash Per Share | 1,135.10 |
| Equity (Book Value) | 31.51B |
| Book Value Per Share | 1,175.04 |
| Working Capital | 38.55B |
Cash Flow
In the last 12 months, operating cash flow was -5.82 billion and capital expenditures -116.49 million, giving a free cash flow of -5.94 billion.
| Operating Cash Flow | -5.82B |
| Capital Expenditures | -116.49M |
| Free Cash Flow | -5.94B |
| FCF Per Share | -222.17 |
Margins
| Gross Margin | 93.54% |
| Operating Margin | -1,948.97% |
| Pretax Margin | -1,298.02% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,602.29% |
Dividends & Yields
CHA Vaccine Research Institute does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.60% |
| Shareholder Yield | -1.60% |
| Earnings Yield | -4.12% |
| FCF Yield | -5.51% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHA Vaccine Research Institute has an Altman Z-Score of 6.58.
| Altman Z-Score | 6.58 |
| Piotroski F-Score | n/a |